Venbio Partners LLCFirm match from fund name (lower confidence)
venBio Global Strategic Fund V, L.P.
Open, writing first checks
Open: first sale Jun 2024, per Form D (fund age approximates vintage)
- Vintage
- 2024
- Fund size
- $504.7M (Form D)
- Stages
- Not stated
- Sectors
- Biotech
- Regions
- Not stated
01 · Thesis
venBio is a life sciences venture investor partnering with teams building novel therapeutics for unmet medical needs, helping companies plan development, clinical trials and potential acquisition partners from the outset.Inferred from the firm's website
02 · Initial check
$5.05M to $8.41M (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Richard Gaster, MD, PhD, Managing Partner
- Yvonne Yamanaka, PhD, Partner
- David Pezeshki, CFA, CPA, Chief Financial Officer
- Aaron Royston, MD, MBA, Managing Partner
- Antoinette Delhonte
- Corey Goodman, PhD, Co-founder and Managing Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideVenbio Partners is a life sciences investment firm focused on novel therapeutics for unmet medical needs.
We are a life sciences investment firm partnering with industry leaders to build game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs.
https://www.venbio.com/
06 · Sources
Last verified: Oct 28, 2026